JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264505

Human FXR1 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

FXR1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9.

View Alternative Names

FXR1P, FXR1_HUMAN, Fragile X mental retardation autosomal homolog 1, Fragile X mental retardation syndrome-related protein 1, hFXR1p

1 Images
Western blot - Human FXR1 knockout HeLa cell lysate (AB264505)
  • WB

Lab

Western blot - Human FXR1 knockout HeLa cell lysate (AB264505)

Lane 1 : Wild-type HeLa cell lysate (20 ug)
Lane 2 :
FXR1 knockout HeLa cell lysate (20 ug)
Lane 3 :
Hep G2 cell lysate (20 ug)
Lane 4 :
A549 cell lysate (20 ug)
Lane 5 :
HEK-293 cell lysate (20 ug)

Lanes 1 - 5 : Merged signal (red and green). Green - ab129089 observed at 70-80 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55 kDa.

ab129089 was shown to react with FXR1 in wild-type HeLa cells in Western blot with loss of signal observed in FXR1 knockout cell line ab264017 (knockout cell lysate ab264505). Wild-type HeLa and FXR1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab129089 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-FXR1 antibody [EPR7932] (<a href='/en-us/products/primary-antibodies/fxr1-antibody-epr7932-ab129089'>ab129089</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

FXR1 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human FXR1 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-fxr1-knockout-hela-cell-line-ab264017'>ab264017</a>)

Lane 3:

HepG2 cell lysate at 20 µg

Lane 4:

A549 cell lysate at 20 µg

Lane 5:

HEK-293 cell lysate at 20 µg

Predicted band size: 70 kDa

Observed band size: 70-80 kDa

false

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Next Generation Sequencing,Western blot

Mutation description

Knockout achieved by CRISPR/Cas9

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab264505-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human FXR1 knockout HeLa cell lysate", "number":"AB264505-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB264505-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
FXR1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The FXR1 protein also known as Fragile X Mental Retardation Syndrome-related Protein 1 weighs approximately 80 kDa and is expressed in various tissues including the brain heart and the skeletal muscles. It belongs to the family of RNA-binding proteins that also includes FMR1 and FXR2. Mechanically FXR1 interacts with mRNA participating in the regulation of its stability and translation. This regulation allows cells to control protein synthesis important for many cellular processes.
Biological function summary

FXR1 is involved in the post-transcriptional regulation of gene expression important for normal cell function and development. It forms a complex with FMRP playing an important role in the transport and translation of specific subsets of mRNAs in neurons. This interaction suggests it contributes significantly to the synaptic plasticity mechanisms influencing learning and memory. Moreover FXR1 also seems to have functions in cell proliferation and muscle differentiation.

Pathways

FXR1 participates in key regulatory pathways of protein synthesis and neuronal communication. It is significant in the mTOR signaling pathway where it potentially interacts with other proteins like FXR2 and FMR1 to modulate translational control. FXR1's involvement in this pathway suggests a role in cellular growth and neuron-specific processes affecting how cells respond to various growth signals by altering protein synthesis rates.

FXR1 links to psychiatric disorders including schizophrenia and bipolar disorder. Gene dysregulation in FXR1 may disrupt normal synaptic functioning contributing to the pathophysiology of these conditions. In muscular dystrophies altered FXR1 expression has been reported associating it with muscle tissue protein dynamics along with FMR1 influencing muscle regeneration and repair mechanisms. These associations highlight FXR1’s potential as a therapeutic target in neurodevelopmental and muscle-related diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com